VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.
about
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cellsOncolytic virotherapy using herpes simplex virus: how far have we come?Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationBevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children.Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.Oncolytic herpes viruses, chemotherapeutics, and other cancer drugsPreparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progressProgress of oncolytic viruses in sarcomas.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Oncolytic Immunotherapy for Treatment of Cancer.The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes.TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma.Tumor Restrictions to Oncolytic Virus.
P2860
Q24618562-466AA696-4EBB-4724-8C07-7B7C50798D66Q26862461-B6BCE74D-2853-47BE-8523-9E0DC8528D09Q33566511-BDE0F291-E1F3-49AA-8EC9-EFAB218217FAQ35665220-93C7B620-CBDC-4D75-B897-17FFD2636577Q36109700-D7327807-041D-4589-8599-1EFF360A4964Q36109704-24BCA397-DA86-4379-8E4B-E704EFBF3119Q36456487-A838FCDD-F6DE-4DDE-BC8A-61ED7A17B9A2Q37031896-E5DBFC7E-875F-4CF3-B6CF-C9D86D29F01FQ37293290-668B0AC4-23D0-4A01-B5E5-148B9DB32322Q37899230-BCCB2903-4F17-4DEC-9CCC-FE1157F5A1B0Q37982449-8AA764EC-B824-4D97-AAB5-0682FECB5A5CQ38223419-56843043-E122-4A00-BE81-DAAE35B5B104Q38848223-4E5E45DE-1759-4B97-AD4E-5182012949FAQ39003657-C96CEB6A-200B-4B2D-BDCC-9E0845D5E5B1Q39405521-ED741467-FB56-4230-BDA0-847DE3A8097EQ42373489-E08C49D5-7E75-40E9-81F2-A715DEEE3412Q51846287-10DDBFB1-4A29-48FB-89EF-0CF9017DBB08
P2860
VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
VEGF blockade decreases the tu ...... when given after virotherapy.
@ast
VEGF blockade decreases the tu ...... when given after virotherapy.
@en
type
label
VEGF blockade decreases the tu ...... when given after virotherapy.
@ast
VEGF blockade decreases the tu ...... when given after virotherapy.
@en
prefLabel
VEGF blockade decreases the tu ...... when given after virotherapy.
@ast
VEGF blockade decreases the tu ...... when given after virotherapy.
@en
P2093
P2860
P356
P1433
P1476
VEGF blockade decreases the tu ...... when given after virotherapy.
@en
P2093
J L Fitzpatrick
M A Currier
R A Gillespie
P2860
P2888
P304
P356
10.1038/GT.2010.82
P577
2010-05-27T00:00:00Z
P5875
P6179
1031901856